Comparative analysis of immunological changes following realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome
- PMID: 38816179
- DOI: 10.1080/08923973.2024.2344158
Comparative analysis of immunological changes following realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome
Abstract
Background: Myelodysplastic syndrome (MDS) is a prevalent hematological neoplastic disorder in clinics and its immunopathogenesis has garnered growing interest. Oral and intravenous arsenic agents have long been used to treat hematological malignancies. The main component of oral arsenic is realgar (arsenic disulfide), while arsenic trioxide is the main component of intravenous arsenic.
Methods: This study aimed to assess the effects of ATO and Realgar on the enhancement of peripheral blood, drug safety, and T cell immune status in the NUP98-HOXD13 (NHD13) mice model of MDS, specifically in the peripheral blood, spleen, and liver.
Results: The study findings indicate that realgar and arsenic trioxide (ATO) can improve peripheral hemogram in mice, whereas realgar promotes higher peripheral blood cell production than ATO. Furthermore, the clinical administration method and dose did not cause significant toxicity or side effects and thus can be considered safe. Coexistence and interconversion of hyperimmune function and immunosuppression in mice were also observed in this study. In addition, there were interactions between immune cells in the peripheral blood, spleen, and liver to regulate the immune balance of the body and activate immunity via T-cell activation.
Conclusion: In summary, oral and intravenous arsenic agents are beneficial in improving peripheral hemogram and immunity in mice.
Keywords: Myelodysplastic syndrome; T lymphocyte subsets changes; arsenic trioxide; fighting poison with poison; realgar.
Similar articles
-
[Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].Zhongguo Zhong Yao Za Zhi. 2020 Jan;45(1):142-148. doi: 10.19540/j.cnki.cjcmm.20190813.403. Zhongguo Zhong Yao Za Zhi. 2020. PMID: 32237423 Chinese.
-
Arsenic concentration in peripheral blood is correlated with efficacy of a Traditional Chinese Medicine regimen containing realgar for the treatment of myelodysplastic syndrome.J Tradit Chin Med. 2021 Aug;41(4):630-635. doi: 10.19852/j.cnki.jtcm.2021.03.016. J Tradit Chin Med. 2021. PMID: 34392657
-
Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.Biol Pharm Bull. 2013;36(4):641-8. doi: 10.1248/bpb.b12-01015. Epub 2013 Jan 25. Biol Pharm Bull. 2013. PMID: 23358330
-
The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.Hematology. 2023 Dec;28(1):2274149. doi: 10.1080/16078454.2023.2274149. Epub 2023 Oct 31. Hematology. 2023. PMID: 37908176 Review.
-
Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.Chin J Integr Med. 2022 Mar;28(3):281-288. doi: 10.1007/s11655-020-3263-8. Epub 2020 May 16. Chin J Integr Med. 2022. PMID: 32418175 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
